China
ESMO 2023 | Ascentage Pharma to Present Results from Two Clinical Studies, including One Oral Presentation, at 2023 ESMO Congress
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it is going to release results from two clinical studies at the 2023 European Society of Medical Oncology (ESMO) Congress.
JinMed’s Nanobathing Products Receive Multiple Patent Certifications and Sign Directed Procurement Agreement with Shanghai Zhongjin HongKang Medical Technology
JinMed has signed a directed procurement agreement for bed-type nanothermal therapy bath cabins with Shanghai Zhongjin HongKang Medical Technology Co., Ltd.
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in its Phase 1 clinical trial of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR mutations.
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the second quarter of 2023 and business highlights.
Innoforce Strengthens Commercialization Leadership and Announces the Appointment of a New Chief Executive Officer
Zhejiang Innoforce Pharmaceuticals Co., Ltd. ("Innoforce"), a CDMO company dedicated to providing one-stop-shop services to Advanced Therapy Medicinal Product (ATMP) customers and partners, today announced Dr. Dewan Zeng as the new Chief Executive Officer, effective immediately.
Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval From NMPA
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Glucagon-like peptide-1 receptor (GLP-1R), Glucagon receptor (GCGR), and Fibroblast growth factor 21 receptor (FGF21R), has completed the dosing of the first subject in the Phase Ib 12-week Multiple-Ascending Dose (MAD) study of DR10624 for the treatment of obesity and hypertriglyceridemia in New Zealand.
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Amarin Corporation plc (NASDAQ:AMRN) and Lotus Pharmaceuticals (1795:TT; “Lotus”) today announced that the two companies have entered into a long-term exclusive partnership to distribute and commercialize VAZKEPA® (icosapent ethyl) across 10 countries, including nine in Southeast Asia (the Association of Southeast Asian Nations - ASEAN) and South Korea.
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13), the innovative, commercial-stage biopharmaceutical company, today reports its unaudited financial results for the six months ended June 30, 2023 and provides updates on key clinical and commercial developments.
NMPA and FDA Approved the First-in-Human Clinical Trial Applications to Evaluate LBL-034, An Anti-GPRC5D/CD3 Bispecific Antibody Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma
Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") announced today that the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) have approved its first-in-human Investigational New Drug (IND) applications for LBL-034, an anti-GPRC5D/CD3 bispecific antibody invented by Leads Biolabs with global intellectual property rights, for the treatment of relapsed/refractory multiple myeloma. Currently, no GPRC5D-targeting antibody has been approved for marketing.
Akeso Inc. Published 2023 Interim Results Positive Profit Alert
Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, today announced that it is expected that the Company will record a profit of not less than RMB2.3 billion for the six months ended June 30, 2023.
